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In mice, disseminated coagulation, inflammation, and ischemia induce neurological
damage that can lead to death. These symptoms result from circulating bubbles
generated by a pathogenic decompression. Acute fluoxetine treatment or the presence
of the TREK-1 potassium channel increases the survival rate when mice are subjected to
an experimental dive/decompression protocol. This is a paradox because fluoxetine is a
blocker of TREK-1 channels. First, we studied the effects of an acute dose of fluoxetine
(50mg/kg) in wild-type (WT) and TREK-1 deficient mice (knockout homozygous KO and
heterozygous HET). Then, we combined the same fluoxetine treatment with a 5-day
treatment protocol with spadin, in order to specifically block TREK-1 activity (KO-like
mice). KO and KO-like mice were regarded as antidepressed models. In total, 167
mice (45 WTcont 46 WTflux 30 HETflux and 46 KOflux) constituting the flux-pool and
113 supplementary mice (27 KO-like 24 WTflux2 24 KO-likeflux 21 WTcont2 17 WTno dive)
constituting the spad-pool were included in this study. Only 7% of KO-TREK-1 treated
with fluoxetine (KOflux) and 4% ofmice treatedwith both spadin and fluoxetine (KO-likeflux)
died from decompression sickness (DCS) symptoms. These values are much lower than
those of WT control (62%) or KO-like mice (41%). After the decompression protocol,
mice showed significant consumption of their circulating platelets and leukocytes. Spadin
antidepressed mice were more likely to exhibit DCS. Nevertheless, mice which had both
blocked TREK-1 channels and fluoxetine treatment were better protected against DCS.
We conclude that the protective effect of such an acute dose of fluoxetine is enhanced
when TREK-1 is inhibited. We confirmed that antidepressed models may have worse
DCS outcomes, but concomitant fluoxetine treatment not only decreased DCS severity
but increased the survival rate.
Keywords: bubble, decompression sickness, diapedesis, kcnk2, TREK-1, diving, depression, capillary leak
Vallée et al. Fluoxetine is More Efficient without TREK-1
INTRODUCTION
In this study, fluoxetine and the new antidepressant spadin were
used to find a treatment strategy against decompression sickness.
Circulating bubbles cause cell damage (Vallee et al., 2013),
prothrombotic phenomena, ischemia, and diapedesis (Dutka
et al., 1989; Zamboni et al., 1989, 1992, 1993; Dal Palu and
Zamboni, 1990; Helps and Gorman, 1991). This inflammation
can spread systemically and may degenerate into a vicious
cycle, ending in multiple organ failure (Jacey et al., 1976;
DeGirolami and Zivin, 1982; Ersson et al., 1998). Spinal cord
and brain neurological damage underlie the most serious
symptoms of decompression sickness (DCS; Gempp et al., 2008).
These symptoms result from circulating bubbles generated by a
pathogenic decompression, following a dive for example. Even
after standard treatment with hyperbaric oxygen, 20–30% of
victims suffer from sequelae after a neurological DCS (Blatteau
et al., 2011). We aimed to establish a potential treatment strategy
using an animal model of DCS.
Fluoxetine, the active compound in the antidepressant
Prozac™, prevents the reuptake of serotonin (5-
hydroxytryptamine, 5-HT) by inhibiting serotonin transporters
(SERT) located in neurons, platelets (Lesch et al., 1993), and
leukocytes (Faraj et al., 1994; Lima and Urbina, 2002; Yang
et al., 2007). SERT increases the concentration of circulating
serotonin (Brenner et al., 2007). When used in a single high dose,
fluoxetine is also believed to mediate neuroprotection (Pariente
et al., 2001; Chollet et al., 2011; Taguchi et al., 2012) by inhibiting
NMDA-R (Vizi et al., 2013), regulating inflammatory effects
(Kubera et al., 2001; Jin et al., 2009; Lim et al., 2009) and algesia
(Kostadinov et al., 2014). We have previously demonstrated that
WT mice treated with fluoxetine are more resistant to DCS and
that fluoxetine inhibits the inflammatory process by reducing the
level of circulating IL-6, a pro-inflammatory cytokine (Blatteau
et al., 2012).
TREK-1, the product of the kcnk2 gene, regulates cell
excitability and prevents neuron death by inhibiting NMDA-
dependent glutamatergic excitotoxicity induced by ischemia
(Franks and Honore, 2004; Heurteaux et al., 2004; Buckler
and Honore, 2005; Honore, 2007; Dedman et al., 2009). The
mechanosensitive TREK-1 channel (Franks and Honore, 2004) is
activated by a mechanical deformation of the cellular membrane,
for example by a deformation induced by air depression
(Heurteaux et al., 2004). Additionally, in mice, decompression-
induced desaturation also activates TREK-1. Consequently, KO
(“KO” is used in the mean of “TREK-1−/− mice”) mice are
more sensitive to DCS thanWT (TREK-1+/+) mice (Vallee et al.,
2012). TREK channel activity is also under the control of several
different mechanisms acting either on channel trafficking and
surface density or directly on gating properties (Noel et al., 2011).
Furthermore, KO mice display a depression-resistant phenotype,
similar to chronic fluoxetine-treated mice (Heurteaux et al.,
2006).
We have shown that the opening of TREK-1 channels is
protective in DCS, suggesting that TREK-1 channel activity limits
ischemia-induced glutamatergic toxicity (Vallee et al., 2012). The
TREK-1 channel is directly inhibited by fluoxetine (Heurteaux
et al., 2006; Bogdan et al., 2011; Sandoz et al., 2011) and by spadin,
a new antidepressant that internalizes the channel after a 5-days
treatment and consequently abolish channel activity (Mazella
et al., 2010; Moha Ou Maati et al., 2011), so the question arises as
to whether acute fluoxetine treatment could be significantly more
efficient when the TREK-1 channel is impaired: we suggest if less
fluoxetine can link to TREK-1, the fluoxetine anti-inflammatory
effect should be enhanced in a dose-dependent manner, although
the neuroprotection afford by the TREK-1 activity could be
loss. Conversely, we wondered whether mice pre-treated with
an anti-depressant drug, that impairs TREK-1 activity, would be
sensitized to DCS.
In this study, we wanted to obtain a better understanding
of the protection afforded by fluoxetine in our DCS model. We
aimed to block the fluoxetine binding on TREK-1, and therefore
to promote other fluoxetine pathways, resulting in a better
efficiency for the inhibition of the NMDA-R or the regulation of
interleukin releases for example (Figure 2).
Before the exposure to the pathogenic decompression, we gave
an acute dose of fluoxetine on wild-type (WT: TREK-1+/+) mice
and on mice to whom TREK-1 disappeared from the membrane
surface. We therefore used TREK-1 knockout (KO: TREK-
1−/−) and heterozygous (HET: TREK-1+/−) mice, or 5 days
of treatment with spadin resulting in KO-like (TREK-1−/−like)
mice, to inhibit TREK-1 channel activity. KO and KO-like mice
were considered the antidepressed models. We obviously did not
use chronic fluoxetine (more than 21 days are necessary) on WT
mice to obtain an antidepressive state, followed by an acute dose
of fluoxetine; while of interest, this would not allow us to reach a
conclusion.
MATERIALS AND METHODS
Animals and Ethical Statement
All procedures involving experimental animals were in line
with European Union rules (Directive 2010/63/EU) and French
law (Decree 2013/118). The ethics committee of the Institut
de Recherche Biomédicale des Armées approved this study.
According to our animal care committee, a scoring system
inspired by the Swiss veterinary guidelines was implemented
to ensure the welfare of animals. A dedicated observer scored
(from 0 to 3) the stress or pain relating to some criteria for
each animal, and then completed a sheet (Supplementary Data).
Pain of degree 3 (very painful) in one case or a total score of
12 in the table were the ethical endpoints. On this sheet, the
most commonly found were: vocalizing, aggression or withdrawn
behavior, reduction in exploratory behavior, licking, closed eyes,
tears, bubbles in the eyes, high respiratory rate, runny nose,
fur bristling, labored breathing, convulsions, paralysis, difficulty
moving, and problems with the fore or rear limbs (classified as
motor disorders). In this study, no score reached 12 and there was
no need to cull the animal based on these criteria. Actually, mice
displaying degree 3 convulsions died very rapidly. At the end of
the experiment, mice were anesthetized first with halothane (5%
in oxygen, Halothane, Belamont, France) in order to gain time
and tominimize stress, and then with an intraperitoneal injection
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of a mixture of 16mg/kg xylazine (Rompum R© 2%, Bayer
Pharma) and 100mg/kg ketamine (Imalgène R© 1000, Laboratoire
Rhône). Our investigator (NV) is associated with agreement
number 83.6 delivered by the Health and Safety Directorate of
our department, as stated in the French rules R.214-93, R-214-
99, and R.214-102. Mice were housed in an accredited animal
care facility. Mice kept were in group cages both during rest
and during the experiments and maintained on a regular day
(6:00 a.m.–6:00 p.m.)/night (12 h) cycle. Food (AO3, UAR) and
water were provided ad libitum and the temperature was kept at
22± 1◦C.
In TREK-1−/− mice, the gene encoding the TREK-1 channel
was knocked out by Cre-Lox recombination (Heurteaux et al.,
2004). The comparator animals were analogous C57Bl/6 mice
(Charles River Laboratory, Arbresle, France). In order to
preclude phenotypic variation between the different strains (Sato
et al., 2006), crosses were made every 11 generations. Wild-
type (WT, TREK-1+/+) heterozygous (HET, TREK-1+/−) and
knockout (KO, TREK-1−/−) mice were produced for this study.
To avoid fluctuations due to female hormonal cycles, only males
were used in this study.
Flux-Pool
In total, 167 mice (6–9 week-old) constituting the flux-pool
were exposed to compressed air to induce DCS. The mice were
randomly divided into four groups and numbered (Figure 1):
46 for the wild-type group treated with fluoxetine (WTflux), 30
for the heterozygous group treated with fluoxetine (HETflux), 46
for the knockout group treated with fluoxetine (KOflux), and 45
wild-type controls (WTcont).
Fluoxetine (50mg/kg) was administered by gavage to
experimental animals as an oral solution (Prozac™ 20mg/5ml,
oral solution bottle of fluoxetine hydrochloride, Lilly
Laboratories, France) 18 h before hyperbaric exposure, while the
wild type control group (WTcont) received a similar saccharine
fluoxetine-free solution (7.4 g/kg). This high dose of fluoxetine
was determined on the basis of previous results from a mouse
model of ischemia (Jin et al., 2009; Blatteau et al., 2012; Taguchi
et al., 2012).
Spad-Pool
In total, 113 mice (strain C57Black/6, 6–9 weeks of age, Harlan
laboratories, Gannat, France) constituted the spad-pool and were
used to replicate the experiment performed with the flux-pool,
but substituting TREK-1 KOmice with spadin-induced KOmice
(KO-like mice). To generate KO-like mice, mice were treated
for 5 days at 9:00 a.m. with intraperitoneal injections of spadin
(100µg/Kg) in a bolus of 100µL of NaCl 0.9%. The mixture
for the acute fluoxetine treatment (50mg/kg; 1.5mg per mouse)
was obtained from 20mg capsules (fluoxetine hydrochloride
Prozac™, Lilly Laboratories, France) diluted in 300µL of a
solution of NaCl 9% and gum arabic 5%. It was injected
intraperitoneally 18 h before the end of the hyperbaric exposure
(p.m. 5:00).
The first group (WTcont2, n = 21), for control, received the
equivalent 5 days of treatment (100µL per day of NaCl 0.9%,
i.p.) plus the vehicle (300µL of NaCl 0.9% with gum arabic 5%)
corresponding to the acute dose of fluoxetine. A second group
(KO-like =WTspadin 5d, n = 27) received a daily dose of spadin
for 5 days plus the vehicle of the acute fluoxetine treatment. A
third group (WTflux2, n = 24) received an acute i.p. injection of
fluoxetine plus the analogous 5 days-treatment without spadin. A
fourth group (KO-likeflux =WTflux+spadin 5d, n = 24) received 5
days of treatment with spadin and the acute dose of fluoxetine. A
fifth group (WTno dive, n = 17) not submitted to the hyperbaric
protocol received the same injections as WTcont2 mice. Batches
were mixed for the hyperbaric protocol.
Hyperbaric Procedure
Hyperbaric Exposure Began at 12:30 p.m.
Each mouse was weighed 30min before the dive. Samples of
20 mice (10 per cage) from the flux-pool or batches of 6–8 mice
from the spad-pool were subjected to the hyperbaric protocol in a
200-l tank fitted with three observation ports. The mice were free
to move around the cage.
FIGURE 1 | Symptoms in different groups of mice 30min after pathogenic decompression as a function of genotype or drug treatment or both. (A) The
flux-pool. (B) The spad-pool. Histogram: black blocks represent the percent of mice that died following the dive (Fatal DCS); gray represents mice that failed at least
one grip test (sensory motor test for forelimbs) (Grip−); white represents the proportion of mice that passed both grip tests (Grip+). Radar Chart: percentage of mice
displaying a type of symptom in a population; cross represents the total (in percent) of Grip− mice, considering that a mouse can present several symptoms at the
same time. WT, wild-type; KO, knockout; HET, heterozygous; KO-like, mice treated for 5 days with spadin. Flux, fluoxetine; cont and cont2, control (no active
molecules). Black * denotes p < 0.05 between groups. Gray * denotes p < 0.10 (trend) between groups.
Frontiers in Physiology | www.frontiersin.org 3 February 2016 | Volume 7 | Article 42
Vallée et al. Fluoxetine is More Efficient without TREK-1
The compression protocol involved two ramps of pressure
increase, first at 0.1 atm/min up to 1 atm, followed by 1 atm/min
up to 9 atm; 9 atm corresponds to the pressure where animals
were kept for 45min before decompression. The decompression
rate was 60 atm/min up to the surface. Compression and
decompression were automatically controlled by a computer
linked to an analog/digital converter (NIUSB-6211, National
Instrument, USA) with two solenoid valves (Belino LR24A-SR,
Switzerland) and a pressure transmitter (Pressure Transmitter
8314, Burket Fluid Control System, Germany). The software was
programmed on a DasyLab (DasyLabNational Instrument, USA)
by our engineer. The software also controlled the temperature
and oxygen rate. Compressed air was generated using a diving
compressor (Mini Verticus III, Bauer Comp, Germany) coupled
to a 100-l tank at 300 bars. The oxygen analyzer was based on
a MicroFuel electrochemical cell (G18007 Teledyne Electronic
Technologies/Analytical Instruments, USA). The temperature
inside the tank was monitored using a platinum-resistance
temperature probe (Pt 100, Eurotherm, France).
Water vapor and CO2 produced by the animals were captured
with soda lime (<300 ppm captured by the soda lime) and
seccagel (relative humidity: 40–60%). Gases were mixed by an
electric fan. The day-night cycle was respected throughout.
Behavioral and Clinical Observations
At the end of the decompression time, mice were observed for
30min. All signs were recorded together with their time of onset:
labored breathing, convulsions or death. Paralysis, difficulty
moving and problems with the fore or rear limbs were classified
as motor deficits.
The grip test, a motor/sensory test adapted from Hall et al.
(Hall, 1985), was used to quantify forelimb involvement 15 and
30min after the end of decompression. The mouse was placed in
the middle of a 60 cm-long cord suspended at a height of 40 cm
hanging from its fore paws and each performance was timed with
a stop-watch, over a test duration of 30 s. Mice which escaped
by climbing up and then walking along the cord corresponded
to the highest score of 30 s. Mice which failed at least one test
were considered as symptomatic (Grip−). The results of this
behavioral test were used to define DCS and distinguished the
following groups: dead (fatal DCS), mice that failed at least one
grip test (Grip−) and mice that passed the grip test (Grip+).
Anesthesia and Sacrifice
All mice were anaesthetized 30min after surfacing (after grip
tests) first with halothane (5% in oxygen, Halothane, Belamont,
France) in order to gain time and to minimize stress, and then
by intraperitoneal injection of a mixture of 16mg/kg xylazine
(Rompum R© 2%, Bayer Pharma) and 100mg/kg ketamine
(Imalgène R© 1000, Laboratoire Rhône). Mice in the spad-pool
were kept for heart blood sampling for biochemistry and then
sacrificed by injecting pentobarbital (200mg/kg ip, Sanofi Santé,
France).
Blood Tests
Blood tests were carried out using an automatic analyzer
(ABCvet, SCIL Animal care company, France) on samples taken
before the dive and again 30min afterwards. The second test
values were corrected according to the hematocrit variation.
Leukocytes, erythrocytes, hematocrit, platelets and Mean Platelet
Volume (MPV)were analyzed in 20µl samples taken from the tip
of the tail and diluted in the same volume of 2mMEDTA (Sigma,
France).
Blood biochemistry [Na+, K+, Ca2+, creatinine kinase,
glucose, blood urea nitrogen (BUN), creatinine, transaminase,
bilirubin, albumin, globulin, total proteins] was conducted with
automatic analyzers (Vetscan VS2, Abaxis Veterinary Company,
France; Reflovet Plus SCIL Animal Care Company, France; and
Accutrend Plus, Roche Diagnostic, USA) on lithium heparin
(Sigma, France) blood samples from the heart. Hemolytic
samples were rejected.
Genotyping
For first part of the study (flux-pool), DNA for PCRwas extracted
from cells from the tip of the tail (5mm) after overnight digestion
at 56◦C with protease K (200µg/ml) (Promega, Charbonnière,
France) freshly added in a buffer solution containing 100mM
Tris (pH 8.5), 200mM NaCl, 5mM EDTA, and 0.2% SDS. The
protease K was then heat-inactivated (95◦C for 5–10min). The
lysate was diluted 20-fold in ultrapure water before amplification.
PCR was carried out on 5µl of lysate added to 20µl of the
reaction mixture. For negative controls, water was substituted
for the lysate. The reaction mixture contained a pair of
primers (10 pM/µl) [1–2] or [1–3] with an amplification mixture
(GoTaq R©Green Master Mix 2X, Promega France). DNA primers
(MWG-Opéron Biotech, France) corresponding to the loci of
interest in the kcnk2 gene (Primers #1 [5′ GGT GCC AGG TAT
GAA TAG AG 3′]; Primers #2 [5′ TTC TGA GCA GCA GAC
TTG G 3′]; Primers #3 [5′ GTG TGA CTG GGA ATA AGA
GG 3′]) were used with the following thermocycler (MultiGene
Gradient, Labnet International, USA) settings: initialization step
94◦C/3min>> [denaturation step 94◦C/25 s >> annealing step
61◦C/25 s >> elongation step 72◦C/35 s] for 35 cycles.
Amplified DNA sequences were resolved by electrophoresis
(Biorad Generator, Powerpac 200; 90V 45min) on buffered
1.2% Tris acetate EDTA agar gels supplemented with BET for
UV detection (Geneflash, Syngene Bioimaging). PCR-detected
bands at both 680 bp [1–2] and 1870 bp [1–3] characterize the
homozygous wild-type (WT, TREK-1+/+), and a single band
at 650 bp [1–3] characterizes the homozygous knock-out (KO,
TREK-1−/−). A pair of bands characterizes heterozygous mice
(HET, TREK-1−/+).
Statistical Analyses
Individual blood cell count data were calculated as the
percentage change from baseline (the measurement before
hyperbaric exposure). Numerical data points are expressed as
mean and standard deviation. A contingency table was used
for independence and association tests coupled with the χ2
significance test. Different groups were compared using the
Mann-Whitney (MW) test and matched comparisons within
groups were analyzed using the Wilcoxon (W) test. Multiple
comparisons were performed using the Kruskal-Wallis test
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followed by the Bonferroni-Dunn post-hoc test. The significance
threshold was 95% with an α-risk of 5%.
RESULTS
Flux-pool: 167 mice (91 WT, 30 HET, and 46 KO) were subjected
to the hyperbaric protocol to induce DCS. In these groups,
mouse weights were similar [weightWTcont: mean = 24.0 ± 2.3 g
(range: 19.4–29.3 g); weightWTflux: mean = 24.2 ± 0.6 g (range:
23.7–25.1 g); weightHETflux: mean = 24.5 ± 2.4 g (range: 20.4–
29.4 g); weightKOflux: mean = 24.4 ± 2.1 g (range: 20.8–30.6 g)]
(KWWTcont/WTflux/HETflux/KOflux: n = 45/46/30/46, α = 0.05,
p = 0.657).
Spad-pool: 113 mice were used in this pool. Spadin was
used to generate TREK-1 KO-like mice. Again, mouse weights
were similar [weight KOlike: mean = 27.4 ± 2.2 g (range:
23.0–31.5 g); weight WTflux: mean = 28.2 ± 2.7 g (range:
23.7–34.4 g); weight KO-like flux: mean = 28.7 ± 2.0 g (range:
25.1–33.0 g) weight WTcont2: mean = 27.2 ± 2.1 g (range: 23.1–
31.3 g); weight WTno dive: mean = 27.2 ± 1.9 g (range: 24.9–
32.6 g)] (KWKO-like/WTflux,/KO-like flux/WTcont2/WTno dive, n =
27/24/24/21/17, p = 0.121). These weights were significantly
higher than those of the flux-pool (KWAllgroups, n =
27/24/24/21/17/45/46/30/46, p < 0.0001), which may increase
susceptibility to DCS.
Hence, in order to avoid confusion, results of both pools, i.e.,
flux and spad, are presented separately.
Clinical Observations
Compared to WT mice, the KO or KO-like mice showed no
abnormal behavioral or phenotypic signs. All groups displayed
a similar range of DCS symptoms (Figure 1).
Most of the mice were prostrate, suggesting that they were
in physiological distress. Symptoms of DCS or death occurred
after returning to the surface. Mice died from convulsions
(on the outer edge of the radar map, Figure 1) and/or
respiratory distress. Mice essentially displayed neurological
symptoms with varying degrees of severity with motor and
locomotor impairments (paraplegia, paraparesis) and, in some
cases, convulsions. We also observed fewer convulsions and
slightly more labored breathing in KO-likeflux (Figure 1B Radar
chart). The opposite trend was found for WTcont2 (Contingency
table, χ2KO-like/WTflux2/KO-like flux/WTcont2/WTno dive = 63.175 vs.
21.026, p < 0.0001).
In the flux-pool, DCS symptoms generally occurred at 5.8 ±
3.5min on average after the end of the dive. When mice
succumbed to DCS, it occurred rapidly, i.e., 6.1 ± 3.1min
on average. There was no significant difference for the onset
of first symptoms or death latency, regardless of the group
(KWWTcont/WTflux/HETflux/KOflux: p = 0.399, p = 0.390,
respectively).
In the spad-pool, first DCS symptoms generally occurred
at 6.2 ± 3.4min on average after the end of the dive. When
mice succumbed from DCS, it occurred more rapidly, at 2.1 ±
4.5min on average. There was no significant difference in the
onset of first symptoms or death, regardless of the treatment
(KW KO-like/WTflux2/KO-like flux/WTcont2/WTno dive: p = 0.620, p =
0.550, respectively).
Lethal DCS, Grip−, Grip+ Status
KOflux and KO-likeflux mice were less susceptible to the
hyperbaric protocol than other groups. Fewer KO-like mice
succeeded in the grip tests (Figure 1 histograms).
Analysis of the different clinical status of DCS showed a
significant difference between the WTcont group and WTflux,
HETflux, and KOflux groups (KWWTcont/WTflux/HETflux/KOflux:
n = 45/46/30/46, α= 0.05, p < 0.0001) (Figure 1;Table 1). Only
7% of KOflux mice died as a consequence of DCS. Additionally,
KOflux mice presented a better success rate in both their grip
tests (Contingency table, χ2WTcont/WTflux/HETflux/KOflux = 39.194
vs. 16.919, n = 45/46/30/46, α = 0.05, p < 0.0001).
In the spad-pool, analysis of the different DCS statuses
showed a significant difference between the different groups
(KW KO-like/WTflux2/KO-like flux/WTcont2/WTno dive: p < 0.0001).
Interestingly, a significant difference appeared between the KO-
like group and the KO-likeflux group. The main difference
corresponded to the number of animals that died from DCS,
i.e., 41 and 4% for the KO-like group and KO-likeflux group,
respectively (Figure 1; Table 1). Surprisingly, the number of
mice that died was lower in the KO-likeflux group than in
the WTflux2 group, i.e., 4 and 17% respectively (Figure 1;
Table 1). The success rate in both grip tests (Grip+) was
lower for the KO-like group (Figure 1; Table 1; Contingency
table, χ2KO-like/WTflux2/KO-like flux/WTcont2/WTno dive = 14.496 vs.
15.507, p = 0.070).
Mice that Failed the Grip Test (Grip−)
Survivors underwent two grip tests (Figure 1; Table 1). While
results of grip tests were different according to the treatment
group, no treatment seems to better promote recovery or worsen
the physical state of mice once symptoms become manifest.
TABLE 1 | Clinical status after a dive.
Populations Clinical status after the hyperbaric exposure
Grip+(%) Grip−(%) Lethal DCS(%)
Flux-pool WT cont 22 16 62
WT flux 46 13 41
HET flux 60 23 17
KO flux 78 15 7
Spad-pool WT cont2 52 19 29
KO-like 26 33 41
KO-like flux 54 42 4
WT flux 2 46 38 17
Survivors underwent two grip tests. Grip tests, i.e., motor/sensory tests, were used to
quantify forelimb involvement 15 and 30min after the end of decompression. Mice which
failed at least one test were considered to be symptomatic (Grip−). The results of this
behavioral test were used to define DCS and distinguish the following groups: dead (Lethal
DCS), mice that failed at least one grip test (Grip−) and mice that passed both grip tests
(Grip+).
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We previously suggested that the absence of TREK-1 channel
activity could limit recovery after DCS (Vallee et al., 2012), but
our present data are not in accord with such a hypothesis. For
example, a large number of KOflux mice passed both grip tests,
but without an improvement between both tests, whereas KO-
likeflux mice not only passed both grip tests, but improved their
scores between test 1 and test 2.
In more detail and with regard to the timed performance
in the grip tests, WTflux mice improved their mean time spent
suspended from the cord (WWTflux: n = 6, α= 0.05, p = 0.034) in
the second test carried out 15min later (16.8 ± 2.1s vs. maximal
time 30.0 ± 0.0 s). In the spad-pool study, better performances
were observed in the second grip tests for the KO-like population
(WKO-like: p = 0.014, 4.1 ± 5.8 s vs. 16.0 ± 11.2 s) and the
KO-likeflux population (WKO-like flux: p = 0.014, 11.5 ± 8.9 s vs.
22.2± 11.1 s).
Significant differences were observed between populations
in both grip tests (first test, KWWTcont/WTflux/HETflux/KOflux :
n = 7/6/7/7, α = 0.05, p = 0.048 and second test, KW
WTcont/WTflux/KOflux: n = 7/6/7/7, α = 0.05, p = 0.039):
the WTcont group did not perform as well as mice treated
with fluoxetine (first test: MW WTcont/KOflux: n = 7/7, p =
0.054, MW WTcont/WTflux: n = 7/6, p = 0.002; second test:
MW WTcont/WTflux: n = 7/6, p < 0.0001). WTflux mice
performed better in the second grip test than HETflux mice
(MWHETflux/WTflux: n = 7/7, p < 0.009). With regard to timed
performance in the grip tests of the spad-pool, no significant
differences were observed between populations, either in the first
(KW: p = 0.190) or second grip test (KW: p = 0.453), or in their
delta performance (KW: p = 0.193).
Full Blood Counts
Erythrocyte Counts
To a small extent, a decrease in red cell counts, usually though
diapedesis, can be observed after a dive and can be attributed
to the decompression protocol (Table 2). Overall, we cannot link
this decrease to an effect of treatment or to mouse genotype.
In the flux-pool, differences in erythrocyte counts could be
attributed to the treatment before the dive (KW: p < 0.0001):
WTcont mice displayed lower erythrocyte counts than both
WTflux (p < 0.001) and KOflux (p < 0.003) mice. HETflux
mice also presented lower erythrocyte counts than KOflux
mice (p = 0.01). Globally, erythrocyte counts decreased
on average after the dive, to a small extent (W: p = 0.003,
mean = −0.4 ± 7.9), with lower counts in Grip− mice
(KW p = 0.017). These differences can therefore be related
to treatments given to the mice (KW p < 0.0001: WTcont
and WTflux presented lower erythrocyte counts than KOflux),
but there were no variations in their consumption rate
(KW p = 0.382) after the dive. This suggests that the
red cell count decrease was due to the decompression,
even when basal levels were different according to
treatment.
In the spad-pool, no effect on erythrocyte counts could be
attributed to the sole effects of treatments before the dive (KW:
p = 0.999), or afterwards (KW: p = 0.392), or in its variation
between before and after the dive (KW: p = 0.172). Following the
dive, a significant decrease in erythrocyte counts (W p < 0.001,
mean = −8.6 ± 10.1) was observed after the decompression
protocol in all survivors, but the variation was not linked to the
clinical state after the dive (Grip+ vs. Grip−: MW p = 0.299:
Grip+: mean= −7.3± 9.4%; Grip−: mean= −10.2± 11.0%).
Platelet Counts
Globally, platelet loss occurs following a dive that can be linked
to the physical state of mice. Platelet consumption seemed to
be more related to the clinical state of the mice than to their
treatment or their genetic status (Table 2). Platelet consumption
increased with the severity of DCS. This drop in platelet counts
was attributed to clotting activity following exposure of the
collagen under bubble-damaged endothelial cells in blood vessels
(Persson et al., 1978; Haller et al., 1987; Thorsen et al., 1987;
Nossum et al., 1999) or to direct interactions between bubbles
and platelets (Hallenbeck et al., 1973; Warren et al., 1973; Giry
et al., 1977).
TABLE 2 | Variation (%) in erythrocyte, leukocyte, and platelet counts before and after decompression.
Correction according to the hematocrit variation Part of the study Variation in blood cell counts between
before and after the hyperbaric exposure (%)
Grip+ Grip− All survivors
Hematocrit 1-Flux-pool −14.4±19.2 −4.5± 25.3 −12.6± 21.6*
2-Spad-pool +29.9±51.8 +31.0± 48.3 +25.2± 43.8*
Erythrocytes 1-Flux-pool −0.6±8.9 0.2± 1.8# −0.4± 7.9*
2-Spad-pool −7.3±9.4 −10.2± 11.0 −8.6± 10.1*
Leukocytes 1-Flux-pool −6.6±66.6 +12.1± 80.8 −2.4± 69.7*
2-Spad-pool −29.0±51.7 −25.4± 74.7 −27.4± 62.8*
Platelets 1-Flux-pool +9.2±33.1 −13.6± 29.2# +4.5± 33.5
2-Spad-pool −26.1±23.8 −41.2± 29.3 −32.7± 27.0*
The column on the right shows the averaged count carried out for all survivors (Grip+ and Grip−). Grip− mice were considered to be symptomatic. Grip+ mice were considered to
be asymptomatic. *Denotes a significant difference within all the survivors between pre- and post-decompression counts. #Denotes a significant difference between Grip+ and Grip−
mice.
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In more detail, and with regards to the first part of the study,
some differences in platelet counts could be attributed to the
treatments before the dive (KW: p < 0.001): WTcont displayed
lower platelet counts than both HETflux (p = 0.004) and KOflux
(p < 0.001). WTflux also presented lower platelet counts than
HETflux (p = 0.004) and KOflux (p < 0.001).
Following the dive, no significant decrease in platelet counts
(mean = +4.5 ± 33.5%) was recorded when all survivors were
considered (W p = 0.728). Nonetheless, Grip− mice tended
to exhibit higher consumption of platelets than Grip+ mice
(KW, p = 0.005; Grip+: mean = +9.2 ± 33.1%; Grip−:
mean = −13.6 ± 29.2%). No link could be established between
platelet consumption and treatments (KW, p = 0.076). This
suggests that platelet consumption, attributed to clotting activity,
is mainly due to the clinical state induced by decompression
rather than to treatment or genotype.
In the spad-pool, the absence of a difference in platelet counts
could be attributed to the treatment effects before the dive (KW:
p = 0.209), and levels before the dive had no consequences on
the clinical state after the dive (KW: p = 0.735).
Thirty minutes after the dive ended, a significant decrease in
platelet counts (−21.2 ± 26.5%) was recorded in all survivors
(MW: p < 0.0001). Platelet consumption was independent of
the nature of the treatment (KW: p = 0.132). Grip+ mice had
more circulating platelets (KW, p = 0.042) and tended to have a
lower consumption (in proportion) of their platelets than Grip−
mice (KW, p = 0.069; Grip+: mean = −26.1 ± 23.8%; Grip−:
mean = −41.2 ± 29.3%). Actually, Grip− platelets had a greater
volume than that of Grip+ mice (p = 0.0014), confirming that
old platelets (with a lower normal volume) had been used in the
aggregation process.
Leukocyte Counts
Globally, there was a loss of leukocyte following the dive (Table 2)
that was usually attributed to diapedesis (Dutka et al., 1989;
Zamboni et al., 1989, 1992, 1993; Dal Palu and Zamboni, 1990;
Helps andGorman, 1991). Neither treatment seemed to influence
leukocyte movement greatly, or the clinical state.
In the flux-pool, differences in leukocyte counts could be
attributed to the treatments before the dive (KW: p = 0.001),
as WTcont displayed lower leukocyte counts than both HETflux
(p = 0.010) and KOflux (p < 0.005). These differences influenced
their clinical state after the dive (KW: p = 0.004). Therefore, mice
that died after the dive-decompression protocol (Lethal DCS
mice) had lower leukocyte counts before the dive than Grip+
mice (4.3± 1.2 vs. 5.3± 1.6× 2.103/µl).
After the dive, in all survivors, leukocyte counts decreased
by 2.4 ± 7.9% (W: p = 0.003). These differences in counts or
variation between the different groups were not significant with
regard to genotype or treatment (KW: p = 0.129 and p = 0.342),
or clinical status after the dive, i.e., Grip+, Grip−, or Lethal (KW
p = 0.870 and p = 0.416).
In the spad-pool, differences in leukocyte counts could be
attributed to the 5 days of spadin treatment (KW, p = 0.008).
KO-like mice displayed higher leukocyte counts than KO-likeflux
mice (p = 0.016), WTflux2 mice (p = 0.007) or WTno dive mice (a
trend, p = 0.096). Differences observed before the dive possibly
influenced the clinical state after the dive (KW: p = 0.022). Here
again, Lethal DCS mice had higher leukocyte counts than Grip+
mice (6.3± 1.7 vs. 5.0± 2.0×02.103/µl, p = 0.032). Nonetheless,
this is the opposite result to what has just been proposed for the
flux-pool study, what must invalidate the hypothesis.
Following the dive, a significant decrease in leukocyte
counts (W: p < 0.0001, mean = −27.4 ± 62.8%) was
recorded in all survivors. Nonetheless, there was no difference
in the consumption of leukocytes between Grip+ and Grip−
mice (KW: p = 0.8930: Grip+: mean = −29.0 ± 51.7%;
Grip−: mean = −25.4 ± 74.7%). Leukocyte recruitment was
independent of the nature the treatment (KW: p = 0.905).
Finally, fluoxetine administered orally before the dive tended
to increase the number of circulating leukocytes, compared to
control mice. When injected i.p., fluoxetine reduced leukocyte
counts. In fact, intraperitoneal injection of fluoxetine induces
irritation and leukocyte adhesion in the abdominal cavity (Herr
et al., 2014). This effect was not counteracted by the 5 days of
spadin treatment, while the latter, when given alone i.p., tended to
increase leukocyte counts. Finally, however, this prestimulation
was equal in all groups for the spad-pool and controlled by
the administration of the vehicle in the same way as fluoxetine
administration. These paradoxical effects on leukocyte counts
before the dive did not influence the (high) survival rate of the
KOflux and the KO-likeflux mice.
As already described (Pontier et al., 2008; Blatteau et al.,
2012; Vallee et al., 2012), the leukocyte counts dropped after
decompression in all survivors, and leukocyte recruitment was
independent of the type of treatment.
Blood Biochemistry
Following the dive, blood biochemistry was assessed on samples
from heart punctures. Compared to WTno dive, sodium (KW:
p = 0.007; post-hoc p = 0.019 p = 0.01), potassium (KW:
p = 0.022; post-hoc p = 0.006 p = 0.004), globulin (KW:
p = 0.01; post-hoc p = 0.008 p = 0.001), and transaminase
(KW: p = 0.001; post-hoc p = 0.002 p < 0.0001) were found
at increased levels in mice subjected to the hyperbaric protocol,
regardless of the clinical state (Grip+ or Grip−) (Table 3). Grip−
mice had higher levels of creatinine kinase (KW p = 0.062;
post-hoc p = 0.019). The BUN level was lower in the Grip+
groupthan in the WTno-dive group (KW p = 0.041; post-hoc
p = 0.016). The albumin level was lower in the Grip+ and the
Grip− groups than in theWTno-dive group (KW: p < 0.001; post-
hoc p = 0.002 p < 0.0001). Triglyceride levels were higher in
Grip− than in Grip+ mice (KW p = 0.005; post-hoc p = 0.01).
Overall, the dive induced a hemoconcentration regarding sodium
potassium and AST levels. This could be due to a capillary leak
consider low albumin levels (in contrast to high globulin levels).
Cell destructions and/or liver shouting could also be engaged,
especially when taking into account high triglycerides levels then
recorded in Grip−. Increase in creatinine kinase also suggested
muscle or heart straining when DCS was stated.
Blood sample analyses from two mice, punctured just before
they died (Lethal DCS) showed (i) higher levels of sodium (KW
p = 0.007; post-hoc p = 0.001), potassium (KW p = 0.022; post-
hoc p = 0.028) or creatinine kinase (KW p = 0.062; post-hoc p =
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TABLE 3 | Blood biochemistry analysis according to clinical status after
the decompression protocol.
Effect of clinical status on: KW Post-hoc test
Total bilirubin 0.004 Lethal DCS < WTno dive p = 0.002
Lethal DCS < Grip+ p < 0.0001
Lethal DCS < Grip− p = 0.002
Na+ 0.007 WTno dive < Lethal DCS p = 0.001
WTno dive < Grip+ p = 0.019
WTno dive < Grip− p = 0.01
Grip+ < Lethal DCS p = 0.031
Grip− < Lethal DCS p = 0.006
K+ 0.022 WTno dive < Grip+ p = 0.0006
WTno dive < Grip− p = 0.004
WTno dive < Lethal DCS p = 0.028
BUN/Urea 0.041 WTno dive > Grip+ p = 0.016
AST/transaminase 0.001 WTno dive < Grip+ p = 0.002
WTno dive < Grip− p < 0.0001
Globulin 0.010 WTno dive < no DCS p = 0.008
WTno dive < DCS p = 0.001
Lactate 0.016 Grip+ < Lethal DCS p = 0.010
Creatinine kinase 0.062 WTno dive < Grip+ p = 0.019
Triglycerides 0.005 Lethal DCS > Grip+ p = 0.005
Grip+ > Grip− p = 0.010
Albumin 0.000 WTno dive > Grip+ p = 0.002
WTno dive > Grip− p < 0.0001
0.064) in comparison with WTno dive mice, (ii) a higher sodium
level in comparison with both the Grip− and Grip+ groups (KW
p = 0.007; post-hoc p = 0.006 and p = 0.031 respectively), (iii)
a higher lactate level (KW p = 0.016; post-hoc p = 0.010) and
triglyceride concentration (KW p = 0.005; post-hoc p = 0.005)
when compared to the Grip+ group, (iv) higher bilirubin levels
than those of WTno dive, Grip+ and Grip−mice (KW p = 0.004;
post-hoc p = 0.002 p < 0.001 p = 0.002, respectively), (v)
unchanged glycemia, calcium, cholesterol, creatinine, and total
protein levels vs. the other groups.
When looking at the effect of the treatments per se on
blood biochemistry after the dive (Table 4), we pointed out
that mice treated with fluoxetine, such as KO-likeflux and
WTflux2 and corresponding to the best survival rates, had
higher levels of potassium (hemoconcentration, cell destruction),
AST (aspartate aminotransferase, liver function) and globulin
(hemoconcentration), and lower levels of albumin (an indicator
of capillary leak) and lactate (high levels indicate anaerobic) than
those of the WTno-dive group.
KO-like mice, receiving spadin for 5 days, displayed the worst
survival rate. In comparison with the WTno-dive group, they
expressed very low levels of bilirubin, a toxic and hydrophobic
TABLE 4 | Blood biochemistry analysis depending on treatment after the
decompression protocol.
Treatment effects on: KW Post-hoc test
Albumin 0.001 WTno dive > KO-likeflux p = 0.001
WTno dive > WTflux2 p < 0.0001
Na+ 0.027 WTno dive < KO-like p = 0.0004
K+ 0.000 WTno dive < KO-likeflux p < 0.0001
WTno dive < WTflux2 p = 0.002
Aspartate T/transaminase 0.000 WTno dive < KO-likeflux p < 0.0001
WTno dive < WTflux2 p < 0.0001
Total bilirubin 0.000 KO-like < KO-likeflux p < 0.0001
KO-like < WTflux2 p < 0.0001
KO-like < WTno dive p = 0.002
Globulin 0.001 WTno dive < KO-likeflux p = 0.001
WTno dive < WTflux2 p = 0.001
Lactate 0.014 KO-like > WTflux2 p = 0.003
Triglycerides 0.029 KO-like > KO-likeflux p = 0.004
KO-like > WTflux2 p = 0.001
breakdown product of red blood cells that is bound to and carried
by albumin. They also had very high levels of lactate (anaerobic
metabolism and possible mitochondria dysfunction), sodium
and triglycerides; the origin of these high triacylglycerol levels
in their blood could be due to adipocyte release, pancreatitis,
autoimmune disease or nephritic syndrome.
DISCUSSION
In this study, fluoxetine should be regarded as an anti-
inflammatory drug, considering that we opted for an acute,
high dose of 50mg/kg; the antidepressant effect of fluoxetine
requires long-term treatment (28 days at 20mg/kg) to induce
synaptogenesis, and should not be considered in this study. In
contrast, 5 days of spadin treatment was sufficient to internalize
TREK-1 channels and consequently to exert antidepressant
activity (Mazella et al., 2010; Moha Ou Maati et al., 2012).
Prevention of Decompression Sickness
The decompression protocol used in this study is comparable
with that used in previous studies on mice of a similar weight
(Berghage et al., 1979; Blatteau et al., 2012; Vallee et al., 2012).
Mice in the spad-pool were heavier, which may have increased
their susceptibility to DCS. Nonetheless, the protocols used in
this study induced neurological DCS with motor and locomotor
impairments and convulsions, suggesting damage to the spinal
cord or brain.
The increase in AST (aspartate aminotransferase) may be
due to fluoxetine hepatotoxicity, as fluoxetine is extensively
metabolized in the liver to norfluoxetine and this is a well-known
side effect (Inkielewicz-Stepniak et al., 2014). Fluoxetine may
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also induce moderate lymphocyte infiltration within the portal
tracts and ballooning degeneration of hepatocytes (Kwak et al.,
2000). The low mortality associated with fluoxetine treatment
led us to conclude that increased AST levels may have a minor
effect on DCS outcomes. Nonetheless and except for Lethal DCS
mice, we also observed increased concentrations of sodium and
potassium ions and globulins, after the dive. These variationsmay
be explained at least in part by hemoconcentration (increased
hematocrit in the spad-pool) or by hepatocyte damage due to the
presence of bubbles in the liver, as previously observed in rats
(L’Abbate et al., 2010). Arguing in favor of liver dysfunction, the
albumin and BUN (both synthetized by the liver) concentrations
were low, but these lower concentrations could also been
explained by damage to the glomerulus, as occurs in nephritic
syndrome (Blann and Ahmed, 2014), or by capillary leak that
may lead to edema (Clarkson et al., 1960). This albumin loss
demonstrated that fluoxetine did not prevent capillary leak per
se, a symptom of severe DCS. Finally, the blood biochemistry
results indicate that damage induced by bubbles may have
induced capillary leak, cell destructions and liver dysfunction.
However, other blood components were not affected by the
dive. Consequently, additional data will be necessary to validate
or invalidate the liver dysfunction hypothesis. Dramatically,
multivisceral dysfunction could be supported by changes in
analyte concentrations in Lethal DCS mice, such as high levels
of creatinine kinase or lactate.
This protocol also decreased erythrocyte, leukocyte and
platelet counts, suggesting diapedesis, inflammation and clotting
activity, as well as ischemia, the usual symptoms described for
DCS. Platelet dysfunction has been described for fluoxetine
(Lesch et al., 1993; Brenner et al., 2007), but this effect did not
influence platelet recruitment or DCS outcomes in our study.
On the other hand, TREK-1 channels are not known to affect
clotting function directly, although they are activated by platelet
activating factor (Maingret et al., 1999). Under these conditions,
TREK-1 channels likely played a minor role in DCS outcomes.
The main result from our work is that mice with impaired
TREK-1 channel function and treated with fluoxetine are more
resistant to the consequences of decompression than WT mice
treated with fluoxetine, and far more resistant than untreated KO
or KO-like mice. Our data suggest that the presence of the TREK-
1 channel may mitigate the global benefit of fluoxetine in DCS-
related ischemia and inflammation. The second important result
from our work is that 5 days of spadin antidepressant treatment,
thereby blocking TREK-1 channel activity specifically, increased
DCS susceptibility. However, when the same 5 days of spadin
treatment was administered to mice treated with fluoxetine, the
protective effect of fluoxetine was increased. These data indicate
that the main protective effect of fluoxetine is mediated by a
cellular pathway independent of TREK-1 channel activity.
Loss of Protective Activity of TREK-1
The high mortality rate of KO-like mice confirmed that the
neuroprotection induced by the TREK-1 channel in WT was
prevented by spadin (5 days of treatment). The importance
of the TREK-1 channel in neuroprotection is well-documented
for different physio-pathological processes, including hypoxia
(Moha Ou Maati et al., 2011), glutamatergic excitotoxicity and
neuronal death (Heurteaux et al., 2004). According to our
previous and present studies (Vallee et al., 2012), mice that do not
express the TREK-1 channel (KO-like or KO) are more likely to
develop neurological symptoms after DCS damage to the central
nervous system. This could be attributed to the stimulation
of NMDA receptor activity, which exacerbated glutamate
excitotoxicity, making the brain blood barrier (BBB) more
permeable to leukocytes (Bittner et al., 2014). These KO mice
are known to display an inflammatory phenotype and accelerated
leukocyte trafficking across the BBB (Bittner et al., 2014).
This study focused on fluoxetine, which inhibited TREK-1
channel activity (Kennard et al., 2005; Sandoz et al., 2011)
and thus reduced its neuroprotective effects. However, in the
present work and in previous experiments on fluoxetine and
DCS (Blatteau et al., 2012), we found that WT mice treated
with fluoxetine were more resistant to DCS than untreated
mice. These observations suggest that the positive anti-
inflammatory effects of fluoxetine outweigh fluoxetine-induced
TREK-1-inhibition.
Enhanced Protective Activity of Fluoxetine
on TREK-1−/−(like) Mice
KO and KO-like mice treated with fluoxetine appeared to be
the most resistant to decompression. It was recently shown that
fluoxetine selectively inhibits glutamate-N2B NMDA receptors
and then induces neuroprotection (Vizi et al., 2013). This
property of fluoxetine could partly substitute for the loss of
TREK-1-mediated neuroprotection. Another hypothesis can also
be drawn. In the absence of TREK-1 channels at the cell
membrane, more fluoxetine may have been available for binding
to other fluoxetine targets, thereby increasing its protective
effects. This hypothesis is suggested by the dose dependence of
DCS in KOflux HETflux and WTflux mice treated with fluoxetine.
We previously attributed the main protective effect of fluoxetine
in DCS to its anti-inflammatory properties from the observed
decrease in IL-6 (Blatteau et al., 2012). Decreased IL-6 secretion
was also described in TREK-1-deficient cells (Schwingshackl
et al., 2012) and this could superimpose on the effect of fluoxetine
to further reduce inflammation in TREK-1 deficient mice. It
could constitute an efficient response to TREK-1−/−-induced
BBB damage (Bittner et al., 2013, 2014) or more hypothetically,
an opportunity to cross the BBBmore readily andmore efficiently
(Figure 2). Finally, fluoxetine is also known to prevent BBB
disruption (Lee et al., 2014) thanks to its anti-inflammatory
activity coupled with its ability to block NMDA receptors and
attenuate glutamatergic excitotoxicity. Further studies will be
required to confirm this hypothesis.
Should SSRI Treatment be a
Contraindication for Diving?
Spadin was described as a new concept of antidepressant and it
was shown that 4 days of treatment with spadin corresponds to
21–28 days of treatment with classical SSRIs (Mazella et al., 2010;
Moha Ou Maati et al., 2012; Borsotto et al., 2015; Devader et al.,
2015; Veyssiere et al., 2015). Spadin treatment induces TREK-
1 internalization, resulting in the disappearance of the channel
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FIGURE 2 | Fluoxetine and possible interactions in a CNS-ischemia model. The circle summarizes the deleterious cascade encountered after a provocative
dive, resulting from vascular bubble formation. Fluoxetine stimulates IL-10 secretion which attenuates the inflammatory response mediated by IL-1, IL-6, and TNF. This
reduces leukocyte infiltration across the BBB. Fluoxetine is also known to selectively block glutamate N2B-containing NMDA receptors (non-synaptic
neurodegenerative), reducing the negative effects of excitotoxicity on neurons. However, blockade of the TREK-1 channel by an SSRI such as fluoxetine may
contribute to the limitation of the protection afforded by these channels, but it may also strengthen the fluoxetine action at other sites in a dose-dependant manner.
from the plasma membrane (Mazella et al., 2010). KO mice are
known for developing a depression-resistant phenotype and also
for being more sensitive to ischemia (Heurteaux et al., 2006).
Both KO and KO-like TREK-1 mice were more likely to succumb
to DCS after dive. Therefore, we legitimately wonder whether
SSRIs, in their usual indication against depression in humans,
could represent a risk factor in diving, or more generally in risky
sports that may induce ischemia and inflammation.
Fluoxetine, TREK-1 and Clinical Status:
Weight
TREK-1 is widely expressed in central and peripheral tissues. It is
highlyexpressedinthenervoussystem,digestivesystem,endocrine
systemand reproductive system, aswell as in themuscular system.
In the CNS, TREK-1 is expressed in both astrocytes and neurons.
It should be kept in mind that fluoxetine, like spadin, could
spread throughout whole body and thus could induce many
interactions not anticipated in this study, even if the symptoms
are mainly nervous. Moreover, it could be useful to include
in further studies immuno-histological technics to confirm the
infiltrating leukocyte population in the brain injury. The signaling
pathways should also be of interest to assess cell viability.
CONCLUSION
We previously found that acute fluoxetine treatment affords
the best protection against DCS when the TREK-1 potassium
channel is impaired. We suggest that this drop in mortality may
be due to decreased ischemia-induced glutamatergic toxicity,
which could be due to the blockage of NMDA receptors by
fluoxetine, and/or to an enhancement of the anti-inflammatory
effect of fluoxetine. Following this study, exact mechanism
remains to be elucidated. We also found that antidepressed
mice, i.e., KO or spadin treated, showed increased susceptibility
to DCS compared to WT mice. It remains to be determined
whether antidepressants could be contraindicated in humans
participating in risky activities such as diving that may induce
ischemia, even though we found an efficient but paradoxical
solution to DCS by delivering fluoxetine.
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